Connect with us

Headlines of The Day

Covaxin shows 77% efficacy in Phase 3 trials, Bharat Biotech informs govt panel

The results of Phase 3 clinical trials of Bharat Biotech’s Covaxin vaccine have come. Data from the Phase 3 trials of Covaxin show the vaccine against Covid-19 is 77.8% effective.

Sources have said Covaxin has shown 77.8% efficacy in the Phase 3 trials conducted across India.

The Subject Expert Committee (SEC) has reviewed Bharat Biotech’s data, but no approval has been given yet. The expert panel met on Tuesday afternoon to review the Covaxin trial results.

The SEC will now send the data to the Drugs Controller General of India (DCGI) for review. Bharat Biotech on Tuesday made a presentation in which the data was presented to the panel, showing 77.8% efficacy of Covaxin. SEC is now looking at the data.

Meanwhile, the World Health Organisation (WHO) has also accepted Bharat Biotech’s Expression of Interest (EoI) for Covaxin and has scheduled a pre-submission meeting tomorrow (June 23). Bharat Biotech expects this to take Covaxin a step closer to getting a WHO emergency use listing (EUL).

Though the meeting will not be a detailed review of the Covaxin vaccine, Bharat Biotech will have an opportunity to submit a summary on the overall quality of the jab, according to the WHO.

The information was provided on the WHO website in the Status of Covid-19 Vaccines within WHO EUL-PQ evaluation process document.

Bharat Biotech had said last month that it expects approval for its Covaxin from the World Health Organisation for emergency use listing during July-September. India Today

Copyright © 2024 Medical Buyer

error: Content is protected !!